Kunimoto H, Kazama K, Takai M, Oda M, Okada M, Yamawaki H. Chemerin promotes the proliferation and migration of vascular smooth muscle and increases mouse blood pressure. Am J Physiol Heart Circ Physiol 309: H1017-H1028, 2015. First published August 7, 2015 doi:10.1152/ajpheart.00820.2014.-Blood chemerin concentration shows positive correlation not only with body mass index and serum triglyceride level but also with systolic blood pressure. While it seems likely that chemerin influences vascular smooth muscle cell (SMC) proliferation and migration, which are crucial to the development of hypertension, this remains to be clarified. In the present study, we investigated whether chemerin controls SMC proliferation and migration in vitro and also affects blood pressure in vivo. In vitro, chemerin significantly stimulated rat mesenteric arterial SMC proliferation and migration, as determined by a cell counting assay and Boyden chamber assay, respectively. The migratory effect of chemerin was confirmed in human aortic SMCs. Chemerin significantly increased ROS production in SMCs and phosphorylation of Akt (Ser 473 ) and ERK, as measured by fluorescent staining and Western blot analysis, respectively. Various inhibitors (ROS inhibitor: N-acetyl-L-cysteine, phosphatidylinositol 3-kinase inhibitor: LY-294002, MAPKK inhibitor: PD-98059, NADPH oxidase inhibitor: gp91 ds-tat, and xanthine oxidase inhibitor: allopurinol) as well as chemokine-like receptor 1 small interfering RNA significantly inhibited chemerin-induced SMC proliferation and migration. Furthermore, chemerin-neutralizing antibody prevented carotid neointimal hyperplasia in the mouse ligation model. In vivo, chronic chemerin treatment (6 g/kg, 6 wk) increased systolic blood pressure as well as phosphorylation of Akt and ERK in the mouse isolated aorta. In summary, we, for the first time, demonstrate that chemerin/ chemokine-like receptor 1 stimulates SMC proliferation and migration via ROS-dependent phosphorylation of Akt/ERK, which may lead to vascular structural remodeling and an increase in systolic blood pressure. 
secretes various hormones, including the adipose tissue-derived cytokine adipocytokine (37) . Chemerin [also known as retinoic acid receptor responder protein 2 (RARRES2) or tazarotene-induced gene 2 protein (TIG2)] is a 16-kDa protein that is encoded by the RARRES2 gene (8) . Chemerin is secreted in an inactive form as 18-kDa prochemerin and is activated after cleavage of the COOH-terminus by inflammation-and/or coagulation-related serine proteases (40) . Chemerin exhibits various effects depending on the way that it is cleaved. For example, chemerin stimulates strong chemotaxis and participates in early inflammation (7) . After a further cleavage of the COOH-terminus by cysteine proteases, in contrast, chemerin inhibits the activation of macrophages and plays anti-inflammatory roles (7) . Chemerin was originally found as a chemoattractant to stimulate chemotaxis of dendritic cells and macrophages at inflammatory sites (35) . In addition, chemerin has been recently recognized as an adipocytokine since chemerin mRNA expression was confirmed in human adipose tissues (3) . Chemerin has a role in promoting adipocyte differentiation (3, 11) . In addition, knockdown of the chemerin gene in differentiated adipocytes reduced the gene expression of glucose transporter type 4, leptin, adiponectin, and perilipin (11) . It also reduced lipolysis, suggesting that chemerin plays a role in lipid metabolism in matured adipocytes (11) . It has been also reported that chemerin causes insulin resistance in primary human skeletal muscle cells (27) . It was further demonstrated in mice fed a high-fat diet that mRNA expression of both chemerin and its specific receptor, chemokine-like receptor (CMKLR)1, increased (25) . An epidemiological study (36) demonstrated that blood chemerin concentration shows positive correlation not only with body mass index and serum triglyceride level but also with systolic blood pressure (SBP). A recent report (34) demonstrated that chemerin was expressed in perivascular adipose tissue and affected contractile reactivity. Therefore, it is likely that chemerin may affect the development of hypertension by directly acting on vascular systems. In the present study, we hypothesized that chemerin may influence vascular smooth muscle cell (SMC) proliferation and migration, which are crucial to the development of hypertension. To test the hypothesis, we investigated whether chemerin stimulates SMC proliferation and migration in vitro and also affects blood pressure in vivo. We, for the first time, found that chemerin increases blood pressure perhaps via stimulating SMC proliferation and migration.
MATERIALS AND METHODS
Approval of animal experiments. Animal care and treatment were done in accordance with institutional guidelines of The Kitasato University and the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals. The animal research was approved by the ethical committee of the School of Veterinary Medicine of The Kitasato University.
Materials. Reagents sources were as follows: recombinant mouse and human chemerin and mouse chemerin-neutralizing antibody (chemerin NAb; R&D Systems, Minneapolis, MN); murine and human platelet-derived growth factor (PDGF)-BB (Pepro Tech, Rocky Hill, NJ); N-acetyl-L-cysteine (NAC), norepinephrine (NE), and BQ-123 (Sigma Aldrich, St. Louis, MO); LY-294002 (Wako, Osaka, Japan); PD-98059 (Cayman, Ann Arbor, MI); gp91 ds-tat (Anaspec, Fremont, CA); allopurinol (LKT Laboratories, St. Paul MN); and rotenone (Enzo Life Science, Farmingdale, NY).
Antibody sources were as follows: total ERK (Santa Cruz Biotechnology, Santa Cruz, CA); phospho-Akt (Ser 473 ), phospho-ERK (Thr 202 /Tyr 204 ), and total Akt (Cell Signaling, Beverly, MA); total actin (Sigma-Aldrich); and CMKLR1 (Bio-World, Dublin, OH).
Culture of rat vascular SMCs. SMCs isolated from the mesenteric artery of male Wister rats under urethane anesthetization (1.5 g/kg ip) were cultured as previously described (32) . SMCs at 80 -90% confluence were growth arrested by an incubation in DMEM containing 0.5% FBS for 24 h before stimulation.
Culture of human vascular SMCs. Human aortic SMCs were obtained from Kurabo (Osaka, Japan) and cultured in DMEM containing 10% FBS as previously described (32) . SMCs were growth arrested by an incubation in DMEM containing 0.5% FBS for 24 h before stimulation.
Cell proliferation analysis. After SMCs were stimulated with chemerin (1-300 ng/ml) for 24 h, cell proliferation was assessed by a colorimetoric cell counting method as previously described (32) . SMCs were pretreated with NAC (5 mM), LY-294002 (20 M), or PD-98059 (50 M) for 30 min before stimulation with chemerin (100 ng/ml, 24 h). We also performed bromodeoxyuridine (BrdU) incor- A: effects of chemerin on smooth muscle cell (SMC) proliferation. After SMCs were stimulated with chemerin (1-300 ng/ml, 24 h), the living cell number was measured by a colorimetoric method (n ϭ 8). The cell number is shown as the fold increase relative to control (Cont). B and C: effects of chemerin on ROS production. Chemerin-induced ROS production was determined by fluorescence staining using 2=,7=-dichlorodihydrofluorescein diacetate (H2DCFDA; n ϭ 4; B) or dihydroethidium (DHE; n ϭ 9; C). After SMCs were stimulated with chemerin (100 ng/ml, 20 min) in the absence or presence of gp91 ds-tat (1-3 M, 2-h pretreatment), allopurinol (100 M, 2 h), or rotenone (15 M, 2 h), they were loaded with H2DCFDA (10 M) or DHE (5 M) for 30 min. Representative photomicrographs are shown. Fluorescent intensity was measured using ImageJ software and is shown as the fold increase relative to control (B). DHE-positive cell number was counted and is shown as the fold increase relative to control (C). Scale bar ϭ 50 m in B or 100 m in C. *P Ͻ 0.05 vs. control; **P Ͻ 0.01 vs. control; #P Ͻ 0.05 vs. chemerin.
poration assay using a commercially available kit (Exalpha Biologicals, Shirley, MA) as previously described (32) . Briefly, cells were seeded at a density of 6 ϫ 10 3 cells/well in a 96-well culture plate. SMCs were stimulated for 24 h with chemerin (100 ng/ml for rat SMCs and 300 ng/ml for human SMCs, respectively). PDGF-BB (10 ng/ml, 24 h) was used as a positive control. BrdU reagent was added to the wells for 12 h in the presence of chemerin. BrdU in the cell was colorimetrically detected.
Measurement of ROS production in vitro. Intracellular ROS production, including hydrogen peroxide, hydroxyl radical, and peroxynitrite, in SMCs was examined by fluorescence staining using 2=,7=-dichlorodihydrofluorescein (H 2DCFDA; Invitrogen, Carlsbad, CA) as previously described (32) . After being stimulated with chemerin (100 ng/ml) for 20 min, SMCs were loaded with H2DCFDA (10 M) for 30 min. SMCs were pretreated with gp91 ds-tat (1-3 M), allopurinol (100 M), or rotenone (15 M) for 2 h before chemerin stimulation (100 ng/ml, 20 min). ROS (superoxide) production in SMCs was also measured by fluorescence staining using dihydroethidium (DHE; Invitrogen). After being stimulated with chemerin (100 ng/ml) for 20 min, SMCs were loaded with DHE (5 M) for 30 min.
Small interfering RNA transfection. Small interfering (si)RNA transfection was performed as previously described (32) . One day after SMCs were subcultured, they (30 -40% confluent) were transfected for 24 h with siRNA against CMKLR1 (CCAUCGUCUU-CAAGUUGCA-dTdT; Nippon Gene Material, Toyama, Japan) or nonsilencing control siRNA (Nippon Gene Material) using Lipofectamine 2000 (Invitrogen) dissolved in Optimem (Invitrogen) at a final concentration of 40 nM.
Boyden chamber assay. To examine SMC migration, a Boyden chamber assay was performed as previously described (32) . Rat SMCs were pretreated with LY-294002 (20 M) or PD-98059 (50 M) for 2 h before chemerin stimulation (100 ng/ml, 6 h). In the experiments using NAC, 600 l serum-free DMEM containing NAC (10 mM) was added to the lower chamber. To analyze human SMC migration, human aortic SMCs were stimulated for 24 h with chemerin (300 ng/ml) in DMEM containing 0.5% FBS. PDGF-BB (10 ng/ml, 24 h) was used as a positive control.
Rhodamine-phalloidin staining. To investigate the reorganization of the actin cytoskeleton, SMCs were stained with rhodaminephalloidin (Cytoskeleton, Denver, CO) after stimulation with chemerin (100 ng/ml) or PDGF-BB (10 ng/ml) for 6 h as previously described (29) .
Western blot analysis. Western blot and data analysis were performed as previously described (32) .
Carotid ligation model. Male BALB/c mice (CLEA Japan, Tokyo, Japan, 18 -20 g, 7 wk old) underwent ligation of the left carotid artery under pentobarbital anesthetization (50 mg/kg ip) as previously described (17) . MedGel PI9 (5 mg/mouse, Wako) containing chemerin NAb (50 g/mouse) or saline (vehicle) was implanted at the site of ligation for 4 wk. After mice were euthanized under urethane anesthetization (1.5 g/kg ip), carotid arteries were harvested. Paraffinembedded sections (4 m) were stained with hematoxylin and eosin. The intima-to-media ratio was calculated using ImageJ software (NIH, Bethesda, MD).
SBP measurement. SBP of C57BL6/N mice (CLEA Japan, 28 -30 g, 13 wk old) was measured using a tail-cuff system (Softron, Tokyo, Japan) in the conscious condition every week as previously described (31) . Mice were divided into a control group (n ϭ 5) or a chemerinadministered group (n ϭ 7). Saline was intraperitoneally administered to the control group (0.18 -0.20 ml/mouse), whereas chemerin was intraperitoneally administered (6 mg·kg Ϫ1 ·day Ϫ1 ) every day for 6 wk. Tissue preparation. After mice had been euthanized under urethane anesthetization (1.5 g/kg ip), the aorta was isolated and used for the extraction of protein and histology (hematoxylin and eosin staining) as previously described (31) .
Measurement of isometric contraction. The main branch of the superior mesenteric artery was isolated from male Wistar rats (CLEA Japan, 180 -390 g) as previously described (31) . Smooth muscle contractility was isometrically measured and recorded as previously described (23) . The concentration-response curve was obtained by a cumulative application of NE (1 nM-1 M).
Statistical analysis. Data are shown as means Ϯ SE. Statistical evaluation was performed using one-way ANOVA followed by the Bonferroni's test. Statistical evaluation between two groups was ). The living cell number was measured by a colorimetric method and is shown as the fold increase relative to control. *P Ͻ 0.05 vs. control; **P Ͻ 0.01 vs. control; #P Ͻ 0.05 vs. chemerin; ##P Ͻ 0.01 vs. chemerin. In D, SMCs were transfected with control small interfering (si)RNA (40 nM) or CMKLR1 siRNA (40 nM) for 24 h (n ϭ 6). After recovery for 24 h, SMCs were stimulated with chemerin (100 ng/ml, 24 h). The living cell number was measured and is shown as the fold increase relative to control siRNA. *P Ͻ 0.05 vs. control siRNA; #P Ͻ 0.05 vs. control siRNA ϩ chemerin. performed using Student's t-test. P values Ͻ 0.05 were considered statistically significant.
RESULTS

Effects of chemerin on SMC proliferation and ROS production.
We first examined the effects of chemerin on SMC proliferation. Chemerin (1-300 ng/ml, 24 h) stimulated SMC proliferation in a concentration-dependent manner (100 ng/ml chemerin: 1.31 Ϯ 0.08-fold relative to control, n ϭ 8, P Ͻ 0.01 vs. control; and 300 ng/ml chemerin: 1.26 Ϯ 0.07-fold, n ϭ 8, P Ͻ 0.05 vs. control; Fig. 1A ). We next examined whether chemerin induces ROS production in SMCs. Chemerin (100 ng/ml, 20 min) significantly increased H 2 DCFDA-sensitive fluorescent intensity (8.42 Ϯ 1.66-fold relative to control, n ϭ 4, P Ͻ 0.01 vs. control; Fig. 1B ). We further examined the mechanisms by which chemerin produces ROS. Pretreatment with gp91 ds-tat (3 M, 2 h), an NADPH oxidase inhibitor, or allopurinol (100 M, 2 h), a xanthine oxidase inhibitor, significantly inhibited chemerin-induced ROS production [chemerin ϩ gp91 ds-tat (3 M): 2.30 Ϯ 0.49-fold, n ϭ 4, P Ͻ 0.05 vs. chemerin; and chemerin ϩ allopurinol: 2.46 Ϯ 1.17-fold, n ϭ 4, P Ͻ 0.05 vs. chemerin; Fig. 1B ], whereas an inhibitor of mitochondrial respiratory chain complex I, rotenone (15 M, 2 h), had no effects on chemerin-induced ROS production (n ϭ 4; Fig. 1B ). Chemerin (100 ng/ml, 20 min)-stimulated ROS (superoxide) production was confirmed by DHE staining (n ϭ 9; Fig. 1C) .
Effects of various inhibitors or CMKLR1 siRNA on chemerin-induced SMC proliferation.
To first clarify whether chemerin-produced ROS mediate SMC proliferation, we examined the effects of pretreatment with NAC (5 mM, 30 min), an antioxidant, on chemerin-induced proliferation. NAC significantly inhibited chemerin-induced SMC proliferation (chemerin: 1.55 Ϯ 0.11-fold relative to control, n ϭ 8, P Ͻ 0.01 vs. control; and chemerin ϩ NAC: 0.89 Ϯ 0.13-fold, n ϭ 8, P Ͻ 0.01 vs. chemerin; Fig. 2A ). It was further confirmed that gp91 ds-tat (10 M, 2 h) significantly inhibited chemerin (100 ng/ml, 24 h)-induced SMC proliferation (n ϭ 8; data not shown). We next investigated whether Akt or ERK signals mediate chemerin-induced SMC proliferation. A phosphatidylinositol 3-kinase inhibitor, LY-294002 (20 M; chemerin: 1.65 Ϯ 0.15-fold relative to control, n ϭ 8, P Ͻ 0.01 vs. control; and chemerin ϩ LY-294002: 1.14 Ϯ 0.14-fold, n ϭ 10, P Ͻ 0.05 vs. chemerin; Fig. 2B ), or an inhibitor of MAPKK, which is an ERK1/2 upstream activator, PD-98059 (50 M; chemerin: 1.31 Ϯ 0.06-fold relative to control, n ϭ 5, P Ͻ 0.05 vs. control; and chemerin ϩ PD-98059: 0.98 Ϯ 0.11-fold, n ϭ 5, P Ͻ 0.05 vs. chemerin; Fig. 2C ), significantly inhibited chemerin-induced SMC proliferation. LY-294002 (20 M; Fig. 2B ) or PD-98059 (50 M; Fig. 2C ) alone had no influence on SMC viability. To further verify whether a specific receptor, CMKLR1, mediates chemerin-induced SMC proliferation, we examined the effects of CMKLR1 gene knockdown on chemerin-induced SMC proliferation. Chemerin-induced SMC proliferation was significantly inhibited by CMKLR1 siRNA (40 nM, 24 h; cont siRNA ϩ chemerin: 1.17 Ϯ 0.05-fold relative to control siRNA, n ϭ 6, P Ͻ 0.05 vs. control siRNA; and CMKLR1 siRNA ϩ chemerin: 1.03 Ϯ 0.05-fold, n ϭ 6, P Ͻ 0.05 vs. control siRNA ϩ chemerin; Fig. 2D ). A: effects of chemerin on SMC migration. Migration of SMCs was determined by a Boyden chamber assay (n ϭ 6). SMCs were stimulated with chemerin (100 ng/ml) for 6 h. The number of migrated cells was randomly counted in three fields (magnification: ϫ100) under a light microscope and averaged and is shown as the fold increase relative to control. Scale bar ϭ 100 m. **P Ͻ 0.01 vs. control. B: effects of chemerin on lamellipodia formation in SMCs. SMCs were stimulated with chemerin (100 ng/ml, 6 h) or platelet-derived growth factor (PDGF)-BB (10 ng/ml, 6 h). The actin cytoskeleton was examined with rhodamine-phalloidin staining (n ϭ 4). Representative photomicrographs of SMCs are shown. Circled areas show lamellipodia formation; arrows in PDGF-BB indicate filopodia formation. Scale bar ϭ 50 m.
Cont
Effects of chemerin on SMC migration and lamellipodia formation. We next examined the effects of chemerin on SMC migration. Chemerin (100 ng/ml, 6 h) stimulated SMC migration significantly (chemerin: 2.45 Ϯ 0.22-fold relative to control, n ϭ 6, P Ͻ 0.01; Fig. 3A) . Reorganization of the actin cytoskeleton (lamellipodia formation) is essential for SMC migration. Therefore, we examined the effects of chemerin on SMC lamellipodia formation. Lamellipodia formation was confirmed by treatment with chemerin (100 ng/ml, 6 h), as shown by thin sheet-like membrane protrusions found at the leading edge (n ϭ 4; Fig. 3B, circles) . On the other hand, filopodia formation was observed by a treatment with PDGF-BB (10 ng/ml, 6 h), as shown by slender needle-like projection found at the leading edge (n ϭ 4; Fig. 3B, arrows) . These results are in accordance with morphological features previously observed during PDGF-BB-stimulated rat mesenteric arterial SMC migration in a Boyden chamber assay (30) .
Effects of various inhibitors or CMKLR1 siRNA on chemerin-induced SMC migration. To investigate whether chemerin-produced ROS mediate SMC migration, we examined the effects of pretreatment with NAC (3 mM, 2 h) on SMC migration. Chemerin-induced SMC migration was significantly inhibited by NAC (chemerin: 4.65 Ϯ 0.84-fold relative to control, n ϭ 4, P Ͻ 0.01 vs. control; and chemerin ϩ NAC: 0.98 Ϯ 0.20-fold, n ϭ 4, P Ͻ 0.01 vs. chemerin; Fig. 4A ). It was further confirmed that gp91 ds-tat (10 M, 2 h) significantly inhibited chemerin (100 ng/ml, 6 h)-induced SMC migration (n ϭ 9; data not shown). Fig. 4C ), significantly inhibited chemerin-induced SMC migration. To further examine whether CMKLR1 mediates chemerin-induced SMC migration, we examined the effects of CMKLR1 gene knockdown. Chemerin-induced SMC migration was significantly inhibited by CMKLR1 siRNA (40 nM, 24 h; control siRNA ϩ chemerin: 2.09 Ϯ 0.09-fold relative to control siRNA, n ϭ 5, P Ͻ 0.01 vs. control siRNA; and CMKLR1 siRNA ϩ chemerin: 0.62 Ϯ 0.03-fold, n ϭ 5, P Ͻ 0.01 vs. control siRNA ϩ chemerin; Fig. 4D ).
Effects of chemerin on the activation of Akt and ERK.
We next examined the effects of chemerin on the activation of Akt and ERK. Chemerin (100 ng/ml, 20 min) significantly stimulated phosphorylation of Akt (Ser 473 ; 2.38 Ϯ 0.34-fold relative to control, n ϭ 8, P Ͻ 0.01; Fig. 5A ) and ERK (Thr 202 /Tyr 204 ; 1.55 Ϯ 0.17-fold relative to control, n ϭ 8, P Ͻ 0.05; Fig. 5B ). To further investigate whether chemerin-produced ROS mediate phosphorylation of Akt and ERK, we examined the effects of pretreatment with NAC (5 mM, 30 min). Chemerin-induced phosphorylation of Akt (chemerin: 1.85 Ϯ 0.15-fold relative to control, n ϭ 10, P Ͻ 0.01 vs. control; and chemerin ϩ NAC: 1.17 Ϯ 0.14-fold, n ϭ 11, P Ͻ 0.01 vs. chemerin; Fig. 5C ) or ERK (chemerin: 1.87 Ϯ 0.23-fold relative to control, n ϭ 16, P Ͻ 0.01 vs. control; and chemerin ϩ NAC: 1.36 Ϯ 0.15-fold, n ϭ 23, P Ͻ 0.05 vs. chemerin; Fig. 5D ) was significantly 
) and ERK (B) was determined by Western blot analysis (n ϭ 8). C and D: effects of NAC on chemerin-induced phosphorylation of Akt (C) and ERK (D).
After pretreatment with NAC (5 mM, 30 min), SMCs were stimulated with chemerin (100 ng/ml, 20 min). Phosphorylation of Akt (Ser 473 ) (n ϭ 10 -11; C) and ERK (n ϭ 16 -23; D) was determined by Western blot analysis and is shown as the fold increase relative to control. Equal protein loading was confirmed using total antibody. *P Ͻ 0.05 vs. control; **P Ͻ 0.01 vs. control; #P Ͻ 0.05 vs. chemerin; ##P Ͻ 0.01 vs. Chemerin. E and F: effects of CMKLR1 gene knockdown on chemerin-induced phosphorylation of Akt (E) and ERK (F). SMCs were transfected with control siRNA (40 nM) or CMKLR1 siRNA (40 nM) for 24 h. After recovery for 24 h, SMCs were stimulated with chemerin (100 ng/ml, 20 min). Phosphorylation of Akt (Ser 473 , n ϭ 3-5; E) and ERK (n ϭ 7-9; F) was determined by Western blot analysis and is shown as the fold increase relative to control siRNA. Equal protein loading was confirmed using total antibody. G: expression of CMKLR1 protein as measured by Western blot analysis and shown as the fold increase relative to control siRNA (n ϭ 6). **P Ͻ 0.01 vs. control siRNA; ##P Ͻ 0.01 vs. control siRNA ϩ chemerin. pAkt, phosphorylated Akt; pERK, phosphorylated ERK.
inhibited by NAC. To further investigate whether CMKLR1 mediates chemerin-induced phosphorylation of Akt and ERK, we examined the effects of CMKLR1 gene knockdown. Chemerin-induced phosphorylation of Akt (control siRNA ϩ chemerin: 1.86 Ϯ 0.12-fold relative to control siRNA, n ϭ 4, P Ͻ 0.01 vs. control siRNA; and CMKLR1 siRNA ϩ chemerin: 1.09 Ϯ 0.07-fold relative to control siRNA, n ϭ 3, P Ͻ 0.05 vs. control siRNA ϩ chemerin; Fig. 5E ) or ERK (control siRNA ϩ chemerin: 1.88 Ϯ 0.17-fold relative to control siRNA, n ϭ 9, P Ͻ 0.01 vs. control siRNA; and CMKLR1 siRNA ϩ chemerin: 1.00 Ϯ 0.13-fold relative to control siRNA, n ϭ 7, P Ͻ 0.05 vs. control siRNA ϩ chemerin; Fig. 5F ) was significantly inhibited by CMKLR1 siRNA (40 nM, 24 h). We confirmed that CMKLR1 protein was successfully silenced by siRNA transfection (n ϭ 6, P Ͻ 0.01; Fig. 5G) .
Effects of chemerin on the proliferation and migration of human SMCs. To explore if the results obtained in rat vascular SMCs are applicable to humans, we examined the effects of chemerin on the proliferation and migration of human vascular SMCs. Recombinant human chemerin (300 ng/ml, 24 h) significantly stimulated the migration of human aortic SMCs (1.40 Ϯ 0.06-fold relative to control, n ϭ 4, P Ͻ 0.05 vs. control; Fig. 6B ), whereas chemerin (300 ng/ml, 24 h) had no effect on SMC proliferation (n ϭ 8; Fig. 6A ). We confirmed that PDGF-BB (10 ng/ml, 24 h) stimulated the proliferation and migration of human aortic SMCs (Fig. 6, A and B) .
Effects of long-term treatment with chemerin NAb on carotid neointimal hyperplasia in the mouse ligation model.
To clarify the effects of chemerin on SMC proliferation and migration in vivo, we examined the effects of long-term treatment with chemerin NAb (50 g/mice, 4 wk) on carotid neointimal hyperplasia in the mouse ligation model. Chemerin NAb significantly prevented neointimal formation compared with vehicle treatment (intima-to-media ratio: 1.34 Ϯ 0.10 for ligation ϩ vehicle and 0.30 Ϯ 0.07 for ligation ϩ chemerin NAB, n ϭ 5-6, P Ͻ 0.01; Fig. 7 ). We confirmed in vitro that chemerin NAb (10 g/ml, 30 min) effectively inhibited chemerin (100 ng/ml)-induced migration of SMCs (n ϭ 11; data not shown).
Effects of long-term treatment with chemerin on SBP in mice. We next investigated the effects of long-term intraperitoneal administration with chemerin (6 wk) on SBP. There was no significant difference in body weight between the control group (n ϭ 5) and chemerin-administered group (n ϭ 7; Fig.  8A ). Significant SBP increases were observed in the chemerinadministered group but not in the control group [chemerin at 16 wk old (increase of SBP from 13 wk old): 9.71 Ϯ 2.49 mmHg, n ϭ 7, P Ͻ 0.05 vs. control; chemerin at 17 wk old: 12.71 Ϯ 7.91 mmHg, n ϭ 7, P Ͻ 0.05 vs. control; chemerin at 18 wk old: 11.86 Ϯ 1.24 mmHg, n ϭ 7, P Ͻ 0.05 vs. control; and chemerin at 19 wk old: 15.57 Ϯ 2.78 mmHg, n ϭ 7, P Ͻ 0.05 vs. control; Fig. 8B] .
Effects of long-term treatment with chemerin on phosphorylation of Akt and ERK in the mouse isolated aorta.
After long-term intraperitoneal administration with chemerin (6 wk), we extracted proteins from the isolated aorta. We then investigated the phosphorylation of Akt (Ser 473 ) and ERK by Western blot analysis. Chemerin significantly increased the phosphorylation of Akt (chemerin: 2.51 Ϯ 0.34-fold relative to control, n ϭ 4 -6, P Ͻ 0.01; Fig. 9A ) and ERK (chemerin: 1.92 Ϯ 0.35-fold relative to control, n ϭ 5-6, P Ͻ 0.05; Fig.  9B ). We further checked if medial hypertrophy occurs in the aorta. There was no significant difference in the wall thickness of the isolated aorta between control and chemerin-treated groups (n ϭ 3; Fig. 9C ). We confirmed that CMKLR1 protein was expressed in the mouse isolated aorta (n ϭ 4; Fig. 9D ). A: after human aortic SMCs were stimulated with chemerin (300 ng/ml, 24 h), a bromodeoxyuridine (BrdU) incorporation assay was performed using a commercially available kit (n ϭ 8). BrdU incorporation is shown as the fold increase relative to control. B: migration of SMCs was determined by a Boyden chamber assay (n ϭ 4). The number of migrated cells is shown as the fold increase relative to control. PDGF-BB (10 ng/ml, 24 h) was used as a positive control. Scale bar ϭ 100 m. *P Ͻ 0.05 vs. control; **P Ͻ 0.01 vs. control.
Control
Effects of chemerin on contractility of the rat isolated mesenteric artery. Contractility of arterial smooth muscle is also an important determinant of blood pressure. We thus finally examined if chemerin affects contractility of the rat isolated mesenteric artery. Chemerin (1-300 ng/ml) alone treatment had no significant influence on basal arterial contractility (n ϭ 5; data not shown). In contrast, chemerin (100 ng/ml, 30 min) pretreatment significantly augmented NE-induced contraction (n ϭ 5; Fig. 10A ). An endothelin receptor antagonist, BQ-123 (5 M, 15 min), inhibited the augmented contraction (n ϭ 4; Fig. 10B ).
DISCUSSION
In the present study, we aimed to elucidate the effects of chemerin on vascular SMC proliferation and migration in vitro as well as on mouse blood pressure in vivo. The major finding of the present study was that chemerin/CMKLR1 stimulates rat Fig. 8 . A: effects of long-term intraperitoneal administration with chemerin on body weight (BW). C57BL/6 mice (13 wk old) were divided into a control group (n ϭ 5) or chemerin-administered group (n ϭ 7). Saline was intraperitoneally administered to the control group (0.18 -0.20 ml/mouse), whereas chemerin was intraperitoneally administered to the chemerin-administered group (6 mg·kg Ϫ1 ·day Ϫ1 ) every day for 6 wk. B: effects of long-term intraperitoneal administration with chemerin on mouse systolic blood pressure (SBP). SBP was measured by the tail-cuff method. The bar graph indicates increments of SBP from the start of vehicle or chemerin administration (at 13 wk old). #P Ͻ 0.05 vs. control. vascular SMC proliferation and migration via ROS-dependent activation of Akt and ERK (Fig. 11) . We also found that long-term intraperitoneal administration with chemerin significantly elevated mouse SBP. The migratory effect of chemerin was confirmed in human aortic SMCs. Our novel data thus represent chemerin as a potential attractive target for the treatment of obesity-related hypertension.
Increase of SBP (mmHg)
A previous report (42) has shown that the human normal plasma chemerin concentration is ϳ50 ng/ml. Another report (3) has shown that the plasma chemerin concentration in hypertensive patients increased to 110 -250 ng/ml. Considering these previous reports, the chemerin concentration (100 -300 ng/ml) used in the present study might be within the pathophysiologically proper range.
In the present study, we, for the first time, showed that chemerin stimulated SMC proliferation and migration via activation of Akt and ERK (Figs. 2, B and C, and 4, B and C) . It has been previously reported that chemerin stimulated proliferation of mouse myoblast C2C12 cells via activation of ERK (38) . Another report (16) has suggested that chemerin/CM-KLR1 mediates activation of Akt and ERK, which might contribute to the maintenance of cell viability in vascular endothelial cells. Furthermore, it has been reported that chemerin stimulated migration of human natural killer cells via activation of ERK (6) . All these reports suggest that chemerin might contribute to cell proliferation and migration by activation of Akt and ERK signals, supporting the results of our present study conducted using vascular SMCs.
In the present study, we elucidated that the actin cytoskeleton change after treatment with chemerin (lamellipodia formation) was different from that after treatment with PDGF-BB (filopodia formation; Fig. 3B) . A previous study (15) has shown that PDGF-BB enhanced the formation of filopodia or lamellipodia during the migration of NIH-3T3 cells. Several lines of evidence indicate that at least two small GTPases of Rho family proteins (the CDC42-GTP pathway or Rac-GTP . A and B: effects of long-term treatment with chemerin on phosphorylation of Akt (A) and ERK (B) in the mouse isolated aorta. C57BL/6 mice (13 wk old) were divided into a control group (n ϭ 5) or chemerin-administered group (n ϭ 7). Saline was intraperitoneally administered to the control group (0.18 -0.20 ml/mouse), whereas chemerin was intraperitoneally administered to the chemerin administration group (6 mg·kg Ϫ1 ·day Ϫ1 ) daily for 6 wk. After proteins were extracted from the isolated aorta, phosphorylation of Akt (Ser 473 , n ϭ 4 -6; A) and ERK (n ϭ 5-6; B) was determined by Western blot analysis. The phosphorylation level was normalized to total protein level and is shown as the fold increase relative to control. *P Ͻ 0.05 vs. control; **P Ͻ 0.01 vs. control. C: medial hypertrophy of the aortic wall was compared. Paraffin-embedded sections (4 m) were stained with hematoxylin and eosin. Representative photomicrographs are shown. The media area to luminal area was measured by ImageJ software and shown in the bar graph (n ϭ 3). Scale bar ϭ 100 m. D: protein expression of CMKLR1 was confirmed in the C57BL/6 mouse isolated aorta by Western blot analysis (n ϭ 4). pathway) contribute to this PDGF-BB-induced migration (5, 12, 15) . On the other hand, it has been reported that fibroblastoid cells formed only lamellipodia during migration, similar to the results of the present study where chemerin treatment was used, and that only the Rac-GTP pathway was activated (13) . Furthermore, it has been suggested that Akt and ERK signals are downstream of Rac-GTP pathway (12) . Therefore, it is likely that chemerin stimulates SMC migration by activation of Akt and ERK, perhaps through the Rac-GTP pathway.
In addition to CMKLR1, chemokine (C-C motif) receptorlike 2 (CCRL2) (39) and G protein-coupled receptor 1 (GPR1) (2) are also known as chemerin receptors. CMKLR1 expression was confirmed not only in adipocytes (3, 11, 25) but also in vascular endothelial cells (16) and SMCs (14) . On the other hand, CCRL2 expression has been confirmed in hematopoietic cells such as monocytes, macrophages, T cells (CD4 ϩ , CD8 ϩ ), natural killer cells, and CD34 ϩ precursor cells in humans (10, 19, 24) . Furthermore, CCRL2 expression has been confirmed in mast cells (41) , astrocytes, microglia (4), and endothelial cells (20) . However, the role of CCRL2 with chemerin is not to activate intracellular signal transduction but to regulate chemerin bioavailability (20, 41) . Thus, CCRL2 does not seem to have a critical role in the chemerin-induced SMC proliferation and migration observed in the present study. On the other hand, it has been reported that GPR1, the recently identified receptor, is expressed in white and brown adipose tissues as well as the stromal vascular fraction (26) . However, GPR1 expression in rat SMCs has not been confirmed so far. It is believed that GPR1 exerts a similar biological activity to CMKLR1 (26) . It might be possible that GPR including GPR1 could activate Rho pathway through arrestin binding. It is known that the Rho pathway is responsible for stress fiber formation (9) . Since chemerin stimulated stress fiber formation in SMCs (Fig. 3B) , it is likely that the GPR1/Rho pathway mediates chemerin-induced SMC migration. However, in the present study, the effect of chemerin on SMC migration was almost completely blocked by CMKLR1 siRNA (Fig. 4D) . Thus, the effect of chemerin on SMCs was mainly dependent on CMKLR1. Further study to clarify the effects of the chemerin/GPR1 pathway on SMC proliferation and migration is needed.
In the present study, we demonstrated that chemerin stimulated ROS production via NADPH oxidase and xanthine oxidase (Fig. 1B) . Several previous studies (29, 30) have demonstrated that ROS stimulate SMC proliferation and migration by activation of Akt or ERK signals. In addition, a previous study (22) has reported that, in the rat isolated aorta, chemerin increased ROS production indirectly by attenuating nitric oxide (NO) production and obstructing NO/cGMP signals. This study suggested that chemerin contributes to ROS production, supporting the results of the present study. On the other hand, it has been reported that chemerin stimulated ROS production via the mitochondrial respiratory chain in human pulmonary artery endothelial cells (28) . Interestingly, our results, showing that chemerin stimulates ROS production independent of the mitochondrial respiratory chain but through NADPH oxidase and xanthine oxidase, were opposite to this report. Although we do not explain the exact reason for this discrepancy, it is presumed that chemerin has different functions depending on the types of cells (human pulmonary artery endothelial cells compared with rat vascular SMCs).
In the present study, we, for the first time, clarified that long-term intraperitoneal administration with chemerin significantly elevated mouse SBP (Fig. 8B) . We could not observe medial thickening in the isolated aorta from chemerin-administrated mice. While we could not do it due to technical Fig. 11 . Proposed model. Chemerin/CMKLR1 stimulates SMC proliferation and migration via NADPH oxidase or xanthine oxidase-induced ROS-dependent phosphorylation of Akt/ERK, which may lead to vascular structural remodeling and an increase in SBP. Chemerin-induced enhanced smooth muscle contractility may also be a potential mechanism contributing to increased blood pressure.
limitations, it is more important to examine arterial remodeling in resistance arteries like the mesenteric artery. The increased ROS production might also be an important factor responsible for the increased SBP. It has been previously demonstrated that blood pressure increased by administration of an inhibitor of glutathione synthesis, which is responsible for ROS removal (33) . In contrast, another report (21) demonstrated that blood pressure decreased by administration of superoxide dismutase, which decomposes ROS. Another important factor responsible for the increased SBP might be the increased contractile reactivity of blood vessels. A previous study (1) has reported that ROS production mediates endothelial dysfunction by attenuating the activity of NO, which is produced in endothelial cells. In the present study, we showed that NE-induced contraction in the isolated mesenteric artery was significantly augmented by chemerin, possibly due to the action of endothelin-1, supporting previous results (18) . Collectively, it is assumed that chemerin-induced ROS production as well as increased contractile reactivity at least partly contribute to the increased SBP in chemerin-administered mice. In summary, we, for the first time, demonstrated that chemerin/CMKLR1 stimulates SMC proliferation and migration via ROS-dependent activation of Akt/ERK, which may lead to vascular structural remodeling and an increase in SBP. Further study on chemerin might contribute to the development of new pharmaceutical therapies for the prevention of hypertensive cardiovascular diseases due to obesity.
